On August 17, 2026, a clinical trial update was recorded for cagrilintide under the study title "A Research Study to Compare Blood Levels of Two Different Versions of Cagrilintide in Adults With Excess Body Weight." The trial, registered as NCT07605052, is a Phase 1 study. Its current status is listed as active, not recruiting, as of the update date.
According to the registry entry, the study is designed to compare blood levels of two different versions of cagrilintide in adults described as having excess body weight. No outcome data, safety findings, or comparative results have been reported in this update. The listing reflects only the trial's phase and recruitment status at this time.
Cagrilintide remains classified as an unapproved compound under research investigation. This update does not indicate any conclusions about the compound's effects, comparative performance, or safety profile. Further information may become available as the trial progresses through its stages.
Readers interested in general background on cagrilintide can consult the compound overview for additional context.